Eton Pharmaceuticals Inc. Stock News

DEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the third quarter ended September 30, 2021.

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -71.43% and -74.55%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for

Tolmars 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists DEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to co-promote ALKINDI SPRINKLE®. Eton will leverage Tolmars 62-person sales force and their existing The post Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE® appeared first on ForexTV .

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the biggest news of the week is Johnson & Johnson''s (NYSE: JNJ ) announcement regarding the spin-off of its Consumer Health business. Eton Pharmaceuticals, Inc. (NASDAQ: ETON )''s topiramate oral solution received approval from the Food and Drug Administration for certain types of seizures in patients two years of age and older and as a preventative treatment of migraine in patients 12 years of age and older. Azurity Pharma, the sponsor of the new drug application, had purchased topiramate, along with two other neurology candidates from Eton. Eton is eligible to receive a $5 million milestone payment and also royalties on sales. Oncorus, Inc. (NASDAQ: ONCR ) was among the biggest decliners of the week following the company''s presentation of early-stage data for a cancer immunotherapy candidate at the Society for Immunotherapy of Cancer conference.

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DEER PARK, Ill., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q2 2021 Results - Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 42.86% and -19.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st

DEER PARK, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases

According to an SEC filing, the FDA action date for Eton Pharmaceuticals Inc's (NASDAQ: ETON) antiepileptic topiramate oral solution has been delayed three months to November 6. An FDA decision was

Wall Street Breakfast (Podcast)

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals Inc (NASDAQ: ETON) has acquired the U.S. and Canadian rights to Crossject's Zeneo hydrocortisone needleless autoinjector. The product is under development as a rescue treatment

Press Release

DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), the U.S. marketer of ALKINDI SPRINKLE®, a treatment for adrenocortical insufficiency in pediatric patients